Biogen reports top-line results from phase 2b study of Natalizumab (332.86)
- The primary and secondary efficacy endpoints were not met in the ACTION 2 study
- Further development of natalizumab in acute ischemic stroke will not be pursued
- Biogen remains committed to advancing treatments for stroke and other acute neurological conditions
- In the middle of 2018, Biogen plans to initiate a global Phase 3 study of BIIB093 in individuals with large hemispheric infarction, where brain swelling (cerebral edema) often leads to high morbidity and mortality.
- Detailed Phase 2b ACTION 2 study findings will be made available in a future scientific forum.